Latest News

Gabapentinoids Increase Exacerbation in COPD


 

TOPLINE:

Gabapentinoid use significantly increased the risk for exacerbations in adults with chronic obstructive pulmonary disease (COPD).

METHODOLOGY:

  • Previous research has prompted warnings from North American and European health agencies of severe exacerbations associated with gabapentinoid use by patients with COPD.
  • The researchers compared data from patients with COPD in Canadian databases between 1994 and 2015 who were new to gabapentinoids and matched them to patients who did not use gabapentinoids.
  • The primary outcome was exacerbation of COPD that required hospitalization in a propensity score-matched study.

TAKEAWAY:

  • The study population included 356 epilepsy patients, 9411 neuropathic pain patients, and 3737 patients with other chronic pain.
  • Use of gabapentinoids was significantly associated with an overall increased risk for severe COPD exacerbation (hazard ratio, 1.49) compared with nonuse.
  • Gabapentinoid use was associated with a significantly increased COPD exacerbation risk for each group of users compared with nonusers, with hazard ratios of 1.58, 1.35, and 1.49 for epilepsy, neuropathic pain, and other chronic pain, respectively.

IN PRACTICE:

“This study supports the warnings from regulatory agencies and highlights the importance of considering this potential risk when prescribing gabapentin and pregabalin to patients with COPD,” the researchers wrote.

SOURCE:

The lead author on the study was Alvi A. Rahman, MSc, of Jewish General Hospital, Montreal. The study was published online on January 16, 2024, in Annals of Internal Medicine.

LIMITATIONS:

A lack of data on smoking status and other residual confounding factors limited the study findings.

DISCLOSURES:

The study was supported by the Canadian Institutes of Health Research and the Canadian Lung Association. Mr. Rahman had no financial conflicts to disclose, but some coauthors disclosed consulting and advisory relationships with various companies, including Merck, Pfizer, Seqirus, Boehringer-Ingelheim, and Novartis outside of the current work.

A version of this article appeared on Medscape.com.

Recommended Reading

Updated Guidelines for COPD Management: 2023 GOLD Strategy Report
MDedge Internal Medicine
Short, long-lasting bronchodilators similar for exacerbated COPD
MDedge Internal Medicine
In-hospital mortality increased in COPD patients with acute exacerbations and high serum phosphate levels
MDedge Internal Medicine
Quitting tobacco can improve lung health in COPD
MDedge Internal Medicine
Blood Eosinophil-Directed Prednisolone Proves Noninferior to Standard Care for COPD Exacerbations
MDedge Internal Medicine
Systemic Bias in AI Models May Undermine Diagnostic Accuracy
MDedge Internal Medicine
CPAP Oversells and Underperforms
MDedge Internal Medicine
Death Risk Takes Decades to Revert to Normal in Ex-Smokers
MDedge Internal Medicine
JAMA Internal Medicine Editor Recaps 2023’s High-Impact Research
MDedge Internal Medicine
High and Low Body Mass Indices Promote Respiratory Symptoms
MDedge Internal Medicine